ApoA-1 Fusion Polypeptides With Dimerization for Longer Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cardiovascular disease, such as recombinant ApoA-1 infusion, face challenges including short half-life, high manufacturing costs, and immunogenicity, necessitating frequent administration and potential toxicity, while ApoA-1 mimetic peptides require daily dosing due to short half-life and high production costs.
Innovation Solution
Development of a fusion polypeptide comprising ApoA1-L1-D, where ApoA1 is linked to a dimerizing domain through a linker (L1), enhancing stability and half-life, and optionally combined with RNase, paraoxonase, or other functional domains to improve therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant ApoA-1 is used for therapy, then cholesterol efflux activity is improved, but half-life is short requiring frequent administration
Solution Approach 1:
The patent combines ApoA-1 with a dimerizing domain to create a fusion polypeptide that forms dimers in circulation. This merging of ApoA-1 with the dimerizing domain doubles the effective concentration and extends half-life by reducing renal clearance, directly resolving the contradiction between maintaining efflux activity and extending duration of action.
2Reliability
If recombinant ApoA-1 is produced at high purity, then therapeutic efficacy is improved, but manufacturing cost increases
Solution Approach 1:
The patent extracts the dimerizing domain from separate purification steps and integrates it into the ApoA-1 fusion polypeptide itself. This allows the dimerization function to be co-expressed and co-purified with ApoA-1, reducing the number of purification steps and lowering manufacturing costs while maintaining therapeutic efficacy.
3Reliability
If ApoA-1 is administered repeatedly, then therapeutic effect is maintained, but immunogenicity increases causing toxicity
Solution Approach 1:
The patent creates a composite fusion polypeptide combining ApoA-1 with a dimerizing domain. This composite structure reduces immunogenicity by creating a more stable, less recognizable foreign structure to the immune system, while the dimerization maintains therapeutic effect through extended circulation and enhanced cholesterol efflux activity upon repeated administration.
4Ease of manufacture
If ApoA-1 mimetic peptides are used, then production cost is reduced, but half-life remains short requiring daily dosing
Solution Approach 1:
The patent merges the ApoA-1 mimetic peptide sequence with a dimerizing domain to create a fusion polypeptide. This combination maintains the cost advantages of peptide-based production while adding dimerization capability that extends half-life by reducing renal clearance, eliminating the need for daily dosing.
Data Source
AI summary
Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.